Some menopausal women in the UK are resorting to posing as men online to obtain testosterone prescriptions due to difficulties accessing the hormone therapy through the National Health Service (NHS). Specialists report a significant increase in referrals for testosterone from primary care for women, struggling to meet the rising demand.
Dr. Louise Olver, who runs a menopause clinic, described the situation as a "postcode lottery," where access to testosterone depends heavily on the specific GP practice and clinician. She noted that while some women find the process straightforward, others encounter significant barriers. Olver has observed instances where women have been prescribed testosterone at levels up to 12 times the safe limit.
The disparity in access is partly attributed to the lack of a specifically licensed testosterone product for women on the NHS. Although a female-specific product is available in private clinics across the UK and has recently received a UK license, it still requires appraisal by the National Institute for Health and Care Excellence (NICE) to determine its cost-effectiveness for NHS use. Discussions with the pharmaceutical industry regarding its cost would also be necessary. Currently, the female product, Androfeme, costs the NHS approximately £100, while the male product, Testogel, is around £30.
Disparities in Prescribing Practices
The prescribing of testosterone for women in the UK is governed by a traffic light system implemented by health boards. In some areas, referred to as 'red' zones, only specialists are permitted to prescribe the drug. Other areas have 'amber' designations, requiring GPs to seek specialist support or agreement before prescribing, or to operate under a shared care agreement where a hospital specialist initiates and monitors the prescription.
"There is no consistency across the board unfortunately," stated one specialist, highlighting the challenges faced by both patients and clinicians in navigating the inconsistent guidelines. The Welsh government has indicated that all health boards are expected to adhere to NICE guidelines for menopause management, including individualized care for Hormone Replacement Therapy (HRT). They are aware that some practitioners prescribe testosterone for women and expect all health boards to follow any future NICE recommendations on the matter.
Potential Benefits and Limitations
Studies suggest that approximately 60% of women may experience benefits from testosterone therapy, particularly in improving libido. However, specialists emphasize the importance of managing expectations, as testosterone is not a universal solution and its effectiveness can vary. Other factors, such as external circumstances or anatomical issues, can also influence intimacy. Comprehensive counseling on the expected outcomes and limitations of testosterone use is crucial for patients.